Jeffrey B. Mirviss Net Worth

The estimated Net Worth of Jeffrey B. Mirviss is at least 20.7 百万$ dollars as of 29 May 2024. Mr Mirviss owns over 63,802 units of Boston Scientific stock worth over 2,324,145$ and over the last 12 years he sold BSX stock worth over 17,522,571$. In addition, he makes 875,743$ as Exec. VP & Pres of Peripheral Interventions at Boston Scientific.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Mirviss BSX stock SEC Form 4 insiders trading

Mr has made over 97 trades of the Boston Scientific stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 63,802 units of BSX stock worth 4,791,530$ on 29 May 2024.

The largest trade he's ever made was selling 63,802 units of Boston Scientific stock on 29 May 2024 worth over 4,791,530$. On average, Mr trades about 9,088 units every 36 days since 2013. As of 29 May 2024 he still owns at least 28,022 units of Boston Scientific stock.

You can see the complete history of Mr Mirviss stock trades at the bottom of the page.

Mr. Jeffrey B. Mirviss biography

Jeffrey B. Mirviss is the Exec. VP & Pres of Peripheral Interventions at Boston Scientific.

What is the salary of Mr Mirviss?

As the Exec. VP & Pres of Peripheral Interventions of Boston Scientific, the total compensation of Mr Mirviss at Boston Scientific is 875,743$. There are 9 executives at Boston Scientific getting paid more, with Michael Mahoney having the highest compensation of 15,764,100$.

How old is Mr Mirviss?

Mr Mirviss is 55, he's been the Exec. VP & Pres of Peripheral Interventions of Boston Scientific since . There are 16 older and 10 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.

What's Mr Mirviss's mailing address?

Jeffrey's mailing address filed with the SEC is 300 BOSTON SCIENTIFIC WAY, , MARLBOROUGH, MA, 01752-1234.

Insiders trading at Boston Scientific

Over the last 20 years, insiders at Boston Scientific have traded over 938,841,783$ worth of Boston Scientific stock and bought 1,398,972 units worth 16,231,539$ . The most active insiders traders include Peter M Nicholas、John E Abele、Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of 4,899,929$. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth 13,212,609$.

What does Boston Scientific do?

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Complete history of Mr Mirviss stock trades at Boston Scientific

Boston Scientific executives and stock owners

Boston Scientific executives and other stock owners filed with the SEC include:

• Michael Mahoney,
  Chairman of the Board, President, Chief Executive Officer
• Daniel Brennan,
  Chief Financial Officer, Executive Vice President
• Joseph Fitzgerald,
  Executive Vice President, President, Interventional Cardiology
• Edward Mackey,
  Executive Vice President - Operations
• David Pierce,
  Executive Vice President and President, MedSurg and President, Endoscopy
• Michael F. Mahoney,
  Chairman, Pres & CEO
• Daniel J. Brennan,
  Exec. VP & CFO
• Joseph M. Fitzgerald,
  Exec. VP & Pres of Interventional Cardiology
• Edward F. Mackey,
  Exec. VP of Global Operations
• Jeffrey B. Mirviss,
  Exec. VP & Pres of Peripheral Interventions
• Edward Ludwig,
  Lead Independent Director
• Charles Dockendorff,
  Independent Director
• David Roux,
  Independent Director
• John Sununu,
  Independent Director
• Donna James,
  Independent Director
• Nelda Connors,
  Independent Director
• Ellen Zane,
  Independent Director
• Stephen MacMillan,
  Independent Director
• Yoshiaki Fujimori,
  Independent Director
• John Sorenson,
  Senior Vice President - Manufacturing and Supply Chain
• Meghan Scanlon,
  Senior Vice President and President, Urology and Pelvic Health
• Scott Olson,
  Senior Vice President and President, Rhythm Management
• Maulik Nanavaty,
  Senior Vice President and President - Neuromodulation
• Wendy Carruthers,
  Senior Vice President - Human Resources
• Desiree Ralls-Morrison,
  Senior Vice President, General Counsel, Corporate Secretary
• Jodi Eddy,
  Senior Vice President, Chief Information Officer
• Eric Thepaut,
  Executive Vice President and President - Europe, Middle East and Africa
• Jeffrey Mirviss,
  Executive Vice President and President - Peripheral Interventions
• Ian Meredith,
  Executive Vice President, Global Chief Medical Officer
• Arthur Butcher,
  Executive Vice President and President, Asia Pacific
• Catherine Jennings,
  VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
• Vance R. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Susan Vissers Lisa,
  VP of Investor Relations
• Jodi Euerle Eddy,
  Sr. VP and Chief Information & Digital Officer
• Jonathan R Monson,
  VP, Global Controller & Chief Accounting Officer
• Vance R Brown,
  SVP, GC and Corp. Secretary
• Timothy A. Pratt,
  EVP & General Counsel
• Supratim Bose,
  EVP & President, Asia-Pacific
• Michael P. Phalen,
  SVP & President, Endoscopy
• Keith D Dawkins,
  Sr. VP, Chief Medical Officer
• Kevin J. Ballinger,
  EVP & Pres, Interven Cardio
• Cheryl Pegus,
  Director
• David S Wichmann,
  Director
• Xin Warren Wang,
  SVP and Pres, Asia Pacific
• Peter M Nicholas,
  Director
• Kristina M Johnson,
  Director
• Nicholas J Jr Nicholas,
  Director
• Karen Prange,
  SVP&Pres, Uro & Women's Health
• Ernest Mario,
  Director
• John E Abele,
  Director
• Uwe E Reinhardt,
  Director
• Katharine T Bartlett,
  Director
• Jean Fitterer Lance,
  SVP & Chief Compliance Officer
• Kenneth Pucel,
  EVP, Operations
• Bruce L Byrnes,
  Director
• John Michael Onuscheck,
  SVP & Pres-Neuromodulation
• Jeffrey D Capello,
  Chief Accounting Officer
• Otha T. Iii Spriggs,
  SVP, Human Resources
• William Kucheman,
  SVP & Group President
• John Raymond Elliott,
  Director
• Lawrence R Neumann,
  SVP and Pres, Emerging Markets
• John B. Pedersen,
  Pres,Uro & Women's Health
• Brian R Burns,
  SVP - Quality
• Ray J Groves,
  Director
• Sam R Leno,
  CFO & EVP Finance & IS
• Stephen F Moreci,
  Sr. VP, Endosurgery
• Marye Anne Fox,
  Director
• Fred Colen,
  EVP
• John E Pepper,
  Director
• James Gilbert,
  EVP
• Donovan Paul,
  SVP, Corporate Comm
• David W Mc Faul,
  Senior VP International
• Ursula M Burns,
  Director
• Warren B Rudman,
  Director
• William F Jr Mcconnell,
  SVP, Administration CRM
• Donald S Baim,
  EVP, Chief Med. & Sci. Officer
• Lucia Luce Quinn,
  Exec. Vice President-HR
• James R Tobin,
  President & CEO
• Paul W Sandman,
  EVP and General Counsel
• Paul A Laviolette,
  COO
• Nancy Ann Deparle,
  Director
• Joel Lawrence Fleishman,
  Director
• David C Habiger,
  Director
• Jonathan Monson,
  SVP, Global Controller and CAO
• Emily Woodworth,
  SVP, Global Controller and CAO
• Jessica L Mega,
  Director
• Susan E Morano,
  Director